
Horizon Space I (HSPOF) to Combine with ArcheNova Biotech in $2Bn Deal
Horizon Space I (OTC:HSPOF) has entered into a definitive agreement to combine with ArcheNova Biotech at a $2 billion valuation. ArcheNova is developing a series of drug candidates and offering its own discovery platform to other firms in the biotech space. More
Nicholas Alan Clayton·Oct 13







